Persistent eosinophilia rarely belongs to one organ.
Eosinophilic disease is a multi-organ expression of type 2 inflammation — including EoE, EGPA, hypereosinophilic syndrome and overlap with severe asthma, CRSwNP and atopic disease. It deserves a unified specialty evaluation.
Why it matters
Untreated eosinophilic inflammation drives progressive tissue damage — airway remodeling, esophageal fibrosis, sinus disease, vasculitis and end-organ injury. Early phenotype recognition opens the door to disease-modifying therapy.
When to seek specialized evaluation
- Persistently elevated blood eosinophils on repeated labs
- Multi-organ symptoms (lung, sinus, skin, GI, nerves)
- Biopsy-proven EoE or food impaction
- Suspected EGPA or eosinophilic vasculitis
- Severe asthma, CRSwNP or atopic disease with elevated eosinophils
How we evaluate
We map the full eosinophilic profile across organ systems, review biomarkers (CBC differential, IgE, ANCA, tryptase), interpret prior imaging and biopsies when available, and structure a phenotype/endotype-driven plan including biologic candidacy.
Advanced treatment options
Targeted biologics (anti-IL-5/5R, anti-IL-4Rα, anti-IgE, anti-TSLP) have reshaped eosinophilic disease care across asthma, CRSwNP, EoE, EGPA and hypereosinophilic syndrome. We orient on current FDA-approved indications and discuss candidacy within the evidence.
Eosinophilic disease is the systemic face of type 2 inflammation.
Mapping eosinophilic involvement across organs frequently reframes the management of severe asthma, sinus and atopic disease.